Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Primary open-angle glaucoma in one eye

• Visual acuity 20/80 or better

• Intraocular pressure in the study eye ≤ 24 mm Hg

• Glaucomatous visual field loss - 7 dB to - 25 dB

Exclusion Criteria:

• Known allergy to brimonidine tartrate

• Uncontrolled systemic disease or infection of the eye

• Recent eye surgery or injections in the eye

• Female patients who are pregnant, nursing or planning a pregnancy